DE-THE-LYCRA-COMPANY
29.9.2022 02:01:44 CEST | Business Wire | Press release
The LYCRA Company,a global leader in developing innovative fiber and technology solutions for the textile and apparel industry, today announced it has entered into an agreement with Qore® to enable the world’s first large-scale commercial production of bio-derived spandex using QIRA®, the next generation 1,4-butanediol (BDO), as one of its main ingredients. This will result in 70% of the LYCRA® fiber content being derived from annually renewable feedstock. This change could potentially reduce the carbon footprint of LYCRA® fiber by up to 44%* versus equivalent product made from fossil-based resources, while maintaining the same high-quality performance parameters of traditional LYCRA® fiber.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005020/en/
The LYCRA Company signs an agreement with Qore® LLC to enable large-scale production of bio-derived spandex. Pictured – Julien Born, CEO of The LYCRA Company (left), and Jon Veldhouse, CEO of Qore® LLC (right), at The LYCRA Company’s headquarters in Wilmington, DE, USA. (Photo: Business Wire)
QIRA® will be produced at Cargill’s biotechnology campus and corn refining operation in Eddyville, Iowa. The facility, which is currently being built, will commence operations in 2024. The first renewable LYCRA® fiber made with QIRA® will be produced at The LYCRA Company’s Tuas, Singapore manufacturing site in 2024. The LYCRA Company is currently seeking commitments with brand and retail customers who are pursuing bio-derived solutions for their apparel.
“As part of our sustainability goals, we are committed to delivering products that support a more circular economy while helping our apparel and personal care customers reduce their footprint,” said Julien Born, CEO of The LYCRA Company. “We are especially pleased to collaborate with Qore®, a company that shares our vision for innovative, sustainable solutions. Their expertise in operating fermentation processes and understanding of the chemical value chains makes them the ideal partner to help develop a bio-derived LYCRA® fiber at commercial scale.”
“We are proud to partner with The LYCRA Company on bringing this sustainable material solution to the market. This collaboration demonstrates that QIRA® directly replaces conventional BDO and thus significantly improves the fiber’s sustainability profile,” said Jon Veldhouse, CEO of Qore®. “QIRA® is an innovative platform chemical that can be used in various applications across industries.”
The first generation of renewable LYCRA® fiber made with QIRA® will use feedstock from field corn grown by Iowa farmers and will enable a significant reduction in CO2 footprint. In addition to replacing a finite resource with an annually renewable one, another benefit for mills, brands and retailers is that there is no change in fiber performance, eliminating the need for any re-engineering of fabrics, patterns, or processes. Equivalent performance was demonstrated in 2014 when the world’s first bio-derived spandex was launched under the LYCRA® brand. The LYCRA Company has since been granted a patent for the process used to make renewable elastane from bio-derived BDO.
For additional information on renewable LYCRA® fiber, The LYCRA Company and Qore® invite interested parties to contact The LYCRA Company sales representatives.
*Estimate from Cradle-to-Gate Screening LCA for a representative LYCRA® fiber manufacturing facility, June 2022, prepared by Ramboll US Consulting, Inc.
About The LYCRA Company
The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, sustainable solutions, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL®. The LYCRA Company’s legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA® fiber. Today, The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. For more information, visit www.thelycracompany.com.
LYCRA® is a trademark of The LYCRA Company.
About Qore® LLC
Formed through a joint venture by Cargill and HELM, Qore® will help leading brands replace fossil-based chemistries with bio-derived intermediates. At the heart of the joint venture is the production of QIRA®, the next-generation bio-derived 1,4-butanediol (BDO). Made biologically through the fermentation of plant-based sugars, QIRA® can save up to 93% of greenhouse gas emissions when replacing today’s widely used chemical intermediates made from traditional fossil sources. Bio-derived QIRA® can be used the same way as its fossil counterpart but with significantly better environmental performance.
For more information, visit www.myqira.com.
Qore® and QIRA® are trademarks of Qore® LLC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220928005020/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release
The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release
Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom